查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929623

檸檬酸馬羅匹坦市場按劑型、類型、最終用戶和分銷管道分類，全球預測（2026-2032年）

Maropitant Citrate Market by Form, Species, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年馬羅匹坦檸檬酸鹽市值為 1.2921 億美元，預計到 2026 年將成長至 1.3912 億美元，預計到 2032 年將達到 2.0384 億美元，複合年成長率為 6.72%。

主要市場統計數據
基準年 2025 1.2921億美元
預計年份：2026年 1.3912億美元
預測年份：2032年 2.0384億美元
複合年成長率 (%) 6.72%

基礎臨床作用和不斷變化的商業性考慮如何影響馬羅匹坦檸檬酸鹽在現代獸醫通訊協定中的應用

檸檬酸馬羅匹坦已成為獸醫學中重要的止吐藥，廣泛用於治療伴侶動物的噁心和嘔吐。臨床醫生和採購負責人越來越認知到其在手術全期護理、化療輔助治療和胃腸道疾病管理中的作用。因此，治療通訊協定正在調整，將馬羅匹坦納入以動物舒適度和縮短復原時間為優先的多模式治療方法中。

臨床實踐的創新、數位分銷的進步以及製劑差異化正在匯聚，從而推動馬羅匹坦檸檬酸鹽的供應和使用方式發生重大變化。

過去幾年，馬羅匹坦檸檬酸鹽在患者獲取途徑、臨床醫生使用方式以及生產商差異化策略方面都發生了變革性變化。其中一項關鍵進展是更專注於開發偏好的口服製劑，以提高飼主遵守用藥和劑量準確性。這種以患者為中心的製劑策略是傳統注射劑的補充，後者在急診和手術全期期仍然至關重要。

關稅驅動的供應鏈重組和策略採購轉變正在影響馬羅匹坦檸檬酸鹽相關人員的業務永續營運連續性和商業策略。

美國近期關稅政策的改變為醫藥原料和獸藥成品的供應鏈韌性和籌資策略帶來了新的考量。關稅調整可能會影響採購成本，並改變國際生產與國內生產的相對競爭力，促使企業重新評估供應商合約和物流模式。為此，企業正優先考慮提高供應鏈透明度，並建立長期的供應商關係，以降低關稅波動帶來的風險。

整合的細分動態動態，包括製劑形式、特異性用途、購買者類型、分銷管道和劑量強度，共同驅動產品系列和分銷管道策略。

深入的細分分析揭示了劑型、目標動物類型、最終用戶、分銷管道和劑量強度如何相互作用，從而影響臨床應用模式和採購決策。劑型差異，例如調味片劑和注射液，決定了給藥環境和飼主對用藥依從性的預期。口服偏好有助於提高門診病人的依從性，而注射劑則有助於急診和手術全期期護理。貓和狗之間的亞型差異至關重要，因為藥物動力學和劑量方面的考慮需要針對不同亞型進行標籤設計和臨床醫生指導，這會影響照護端的藥物儲備選擇。

美洲、歐洲、中東和非洲以及亞太地區的區域監管差異、分銷偏好和臨床應用趨勢正在影響商業化策略。

區域因素持續影響美洲、歐洲、中東、非洲和亞太地區的監管一致性、臨床實踐模式和分銷模式。在美洲，完善的獸醫網路和強大的專科獸醫服務支援快速採用創新配方和特殊劑量方案，而完善的低溫運輸基礎設施則確保了注射劑產品的可靠分銷。放眼東方，歐洲、中東和非洲的法律規範和報銷環境各不相同，因此需要製定量身定做的市場進入策略以及區域性的標籤和藥物監測方法。

因此，制定一項結合了強力的監管計劃、本地臨床合作和靈活的分銷能力的地理策略，以滿足每個地區不同的市場結構和臨床醫生的期望，是成功的關鍵。

製造商和經銷商之間的競爭日益集中於透過配方創新、通路夥伴關係附加價值服務來實現差異化。主要企業正致力於改善偏好、拓展劑量規格並最佳化注射劑配方，以確保在急診環境中提供穩定的療效。同時，經銷商和第三方合作夥伴也不斷提升服務水平，包括整合低溫運輸物流、庫存管理解決方案以及數據驅動的需求預測，以更好地支援獸醫診所和專科中心。

綜上所述，這些公司層面的策略強調了協調產品開發、供應鏈卓越性和臨床醫生合作對於在馬羅匹坦檸檬酸鹽領域保持永續商業性優勢的重要性。

為了平衡臨床價值和商業性價值，產業領導者應優先考慮整合產品系列設計、供應鏈韌性和臨床醫生協作的綜合方法。首先，投資以患者為中心的製劑研發，以改善口服偏好，並為多種劑量規格提供明確的臨床依據，從而滿足不同的臨床需求，並提高門診患者的依從性。其次，透過多元化採購管道、盡可能將製造地地點設在更靠近患者的地方以及加強低溫運輸夥伴關係，強化供應鏈策略，以確保注射劑在整個分銷網路中的品質。

採用穩健的多源資訊來源調查方法，整合醫療專業人員訪談、監管審查和細分市場分析，以產生可操作的商業和臨床見解。

本研究整合了一手和二手證據，並採用結構化的調查方法，得出反映當代臨床實踐和商業性現實的結論。一手資料包括對執業獸醫、採購人員和分銷主管的訪談，以深入了解製劑偏好、分銷管道績效和臨床應用案例。這些質性研究結果與二級資訊來源（包括同儕審查的藥理學文獻、監管文件和產業技術報告）進行三角驗證，以檢驗臨床和安全性的考量。

整合臨床效用、分銷管道發展和供應鏈優先事項，以明確策略重點，從而實現持續的商業性成功和改善患者預後。

總之，檸檬酸馬羅匹坦仍是獸醫學中重要的止吐藥，在手術全期護理、輔助性治療化療和胃腸功能障礙的治療中具有顯著的臨床效用。然而，由於多種因素的影響，這種格局正在發生變化，例如：人們越來越關注偏好更好的口服製劑、配銷通路多元化（包括線上藥房）以及貿易政策變化導致供應鏈監管力度加大。這些因素共同要求生產者、經銷商和獸醫服務提供者採取更全面的策略，以平衡臨床需求和營運韌性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 檸檬酸馬羅匹坦市場依劑型分類

  • 調味片
  • 注射液

9. 檸檬酸馬羅匹坦市場（按類型分類）

  • 貓
  • 狗

第10章 檸檬酸馬羅匹坦市場（依最終用戶分類）

  • 獸醫院
  • 動物診所
  • 獸醫診所

第11章 馬羅匹坦檸檬酸鹽市場（依通路分類）

  • 線下藥房
  • 網路藥房
    • 製造商平台
    • 第三方零售商

第12章 馬羅匹坦檸檬酸鹽市場區域分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 檸檬酸馬羅匹坦市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國馬羅匹坦檸檬酸鹽市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國馬羅匹坦檸檬酸鹽市場

第17章：中國的馬羅匹坦檸檬酸鹽市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alivira Animal Health Limited
  • Ashish Life Science Pvt. Ltd.
  • Aurobindo Pharma Limited
  • Bimeda Holdings plc
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Hester Biosciences Limited
  • HIPRA, SA
  • Intas Pharmaceuticals Ltd.
  • KVP Pharma+Veterinar Produkte GmbH
  • Lasa Supergenerics Limited
  • Merck Animal Health
  • Neogen Corporation
  • Norbrook Laboratories Limited
  • Pharmgate Animal Health
  • Sequent Scientific Limited
  • Venkateshwara Hatcheries Limited
  • Vetindia Pharmaceuticals Limited
  • Vetoquinol SA
  • Virbac SA
  • Zim Laboratories Limited
  • Zoetis Inc.
  • Zydus Animal Health
Product Code: MRR-0A3806951852

The Maropitant Citrate Market was valued at USD 129.21 million in 2025 and is projected to grow to USD 139.12 million in 2026, with a CAGR of 6.72%, reaching USD 203.84 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 129.21 million
Estimated Year [2026] USD 139.12 million
Forecast Year [2032] USD 203.84 million
CAGR (%) 6.72%

Foundational clinical role and evolving commercial considerations shaping maropitant citrate adoption in modern veterinary therapeutic protocols

Maropitant citrate has emerged as a pivotal antiemetic agent in veterinary medicine, widely used to manage nausea and vomiting across companion animal care. Clinicians and procurement professionals increasingly recognize its role in perioperative care, chemotherapy support, and management of gastrointestinal disturbances. As a result, therapeutic protocols are adapting to incorporate maropitant into multimodal regimens that prioritize animal comfort and faster recovery times.

In parallel, advances in formulation science and distribution pathways have expanded access to both tablet and injectable presentations, enabling veterinarians to match administration routes to clinical scenarios and owner preferences. Regulatory frameworks continue to evolve to reflect safety profiling and pharmacovigilance insights, which in turn shapes labeling, recommended dosing, and approved indications. Consequently, manufacturers and veterinary providers must stay attuned to these regulatory nuances to ensure compliant use and effective patient outcomes.

Moreover, stakeholder expectations around product differentiation, such as palatability, dosage flexibility, and cold-chain logistics for injectables, are influencing procurement decisions. Therefore, understanding the intersection of clinical efficacy, formulation attributes, and supply chain considerations is essential for organizations seeking to optimize therapeutic protocols and commercial positioning in the maropitant citrate space

Converging clinical practice innovations, digital distribution evolution, and formulation differentiation driving significant shifts in maropitant citrate delivery and usage

The last several years have been marked by transformative shifts in how maropitant citrate reaches patients, how clinicians deploy it, and how manufacturers differentiate their products. One major development has been the increasing emphasis on palatable oral formulations that improve owner compliance and dosing accuracy. This shift toward patient-centric formulation design complements traditional injectable options that remain indispensable in acute care and perioperative settings.

Concurrently, digital channels and telehealth consultations have altered prescription pathways, enabling faster triage and earlier initiation of antiemetic therapy. As a result, distribution strategies have diversified to include more robust online pharmacy offerings alongside established veterinary supply chains. These distribution changes are supported by advances in cold-chain logistics for injectables, ensuring product integrity across longer and more complex supply routes.

Additionally, clinical practice guidelines and consensus statements have increasingly recommended proactive antiemetic use in specific high-risk scenarios, prompting wider adoption among specialty hospitals and general clinics alike. At the same time, competitive differentiation through dosing convenience, expanded dosage strength options, and clearer safety communication are driving product positioning strategies. Taken together, these shifts demand coordinated responses from manufacturers, distributors, and clinicians to translate innovation into improved patient care and better operational outcomes

Tariff-driven supply chain recalibrations and strategic sourcing shifts shaping operational resilience and commercial tactics for maropitant citrate stakeholders

Recent tariff policy changes in the United States have introduced new considerations for supply chain resilience and sourcing strategy for pharmaceutical inputs and finished veterinary products. Tariff adjustments affect procurement costs and can alter the relative competitiveness of international manufacturing versus domestic production, prompting firms to reassess supplier contracts and logistics models. In response, companies are prioritizing supply chain visibility and longer-term supplier relationships to mitigate exposure to tariff volatility.

Consequently, manufacturers and distributors are evaluating nearshoring options and diversified sourcing strategies to maintain stable access to both active pharmaceutical ingredients and finished dosage forms. This strategic repositioning is taking place alongside investment in inventory buffering and advanced demand-sensing techniques that reduce the risk of stockouts while controlling holding costs. Additionally, contracting terms with third-party logistics providers and distributors are being renegotiated to reflect new cross-border cost structures and to secure more flexible fulfillment terms.

From a commercial perspective, organizations are also reviewing pricing frameworks, rebate structures, and tender participation strategies to sustain margin profiles under altered cost conditions. At the same time, regulatory compliance and documentation for customs and import controls have become focal points to avoid delays. In short, the tariff environment is reshaping operational priorities across manufacturing, distribution, and commercial teams, encouraging a more strategic and resilient approach to supply chain and pricing decisions

Integrated segmentation dynamics across formulation, species-specific use, purchaser type, distribution pathways, and dosage strengths driving portfolio and channel strategies

Insightful segmentation analysis reveals how form, species, end user, distribution channel, and dosage strength interact to influence clinical adoption patterns and procurement decisions. Form variations such as flavored tablets and injectable solution determine administration settings and owner compliance expectations, with oral palatability supporting outpatient adherence and injectable forms serving acute and perioperative care pathways. Species differentiation between cat and dog is critical because pharmacokinetic and dosing considerations necessitate species-specific labeling and clinician guidance, thereby influencing stocking choices at point of care.

End-user distinctions among animal specialty hospitals, veterinary clinics, and veterinary hospitals affect purchasing cadence, volume agreements, and clinical protocols; specialty hospitals often drive adoption of expanded strength options and novel formulations, whereas general clinics prioritize versatile dosing and ease of administration. Distribution channel dynamics span direct sales, online pharmacy, and third-party distributor routes; direct sales encompass key account sales and tender sales and support strategic relationships with large institutional buyers, while online pharmacy options include manufacturer platforms and third-party retailers that facilitate consumer access and subscription models. Third-party distribution further segments into pharmaceutical distributors and veterinary supply wholesalers that optimize reach across practice types.

Dosage strength options-10 mg/mL injectable and tablet forms in 16 mg, 32 mg, and 64 mg strengths-provide clinicians with flexibility to tailor dosing to weight and clinical need, shaping inventory strategies and SKU rationalization decisions among purchasers. Together, these segmentation layers underscore the necessity for manufacturers to offer a coherent portfolio and distribution strategy aligned to the clinical realities and purchasing behaviors of diverse veterinary stakeholders

Regional regulatory diversity, distribution preferences, and clinical adoption trends across Americas, Europe Middle East & Africa, and Asia-Pacific shaping commercialization strategies

Regional considerations continue to influence regulatory alignment, clinical practice patterns, and distribution models across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, established veterinary care networks and strong veterinary specialty services support rapid uptake of formulation innovations and specialty dosing options, while established cold-chain infrastructure enables reliable distribution of injectable products. Moving eastward, the Europe, Middle East & Africa region presents a mosaic of regulatory frameworks and reimbursement environments, requiring tailored market access strategies and regionally adapted labeling and pharmacovigilance approaches.

Meanwhile, the Asia-Pacific region is characterized by rapidly expanding companion animal ownership and growing investment in veterinary services, which creates opportunities for broader product penetration but also necessitates attention to local registration pathways and pricing dynamics. Across all regions, distribution channel preferences vary; some markets show pronounced growth in online pharmacy activity and e-prescribing platforms, while others remain anchored in traditional veterinary supply chains. These regional differences have direct implications for launch sequencing, supply chain design, and local commercialization investments.

Therefore, successful geographic strategies combine robust regulatory planning, localized clinical engagement, and flexible distribution arrangements to address distinct market structures and clinician expectations in each region

Competitive dynamics among manufacturers and distributors are increasingly focused on differentiation through formulation innovation, channel partnerships, and value-added services that support clinical outcomes. Leading players have concentrated on enhancing palatability, expanding dosage strength assortments, and refining injectable formulations to deliver consistent performance in acute care settings. In parallel, distributors and third-party partners have strengthened service offerings such as integrated cold-chain logistics, inventory management solutions, and data-driven demand forecasting to support veterinary practices and specialty centers.

Strategic collaborations between manufacturers and large institutional buyers are also notable, where customized supply agreements and clinical support programs provide mutual benefits in terms of product availability and evidence generation. At the same time, smaller innovators and contract manufacturers are carving out niches by offering flexible production runs and targeted formulations for specific clinical scenarios. Competitive positioning increasingly leverages post-market safety data, real-world evidence, and clinician education programs to build trust and encourage guideline-based use.

Taken together, these company-level strategies emphasize the importance of aligning product development, supply chain excellence, and clinician engagement to maintain a sustainable commercial advantage in the maropitant citrate segment

Industry leaders should prioritize an integrated approach that aligns portfolio design, supply chain resilience, and clinician engagement to capture clinical and commercial value. First, invest in patient-centric formulation development that improves oral palatability and offers a clear clinical rationale for multiple dosage strengths, thereby addressing diverse practice needs and enhancing adherence in outpatient contexts. Next, reinforce supply chain strategies by diversifying sourcing, establishing nearer-term manufacturing options where feasible, and strengthening cold-chain partnerships to secure injectable product integrity across distribution networks.

Furthermore, expand channel strategies to include robust online pharmacy capabilities alongside traditional distributor relationships, supported by clear compliance frameworks and digital patient education assets. Concurrently, deepen clinical engagement through targeted education programs, real-world evidence initiatives, and guideline contribution to drive appropriate use in perioperative and oncology settings. From a commercial perspective, reassess pricing and contracting approaches to reflect evolving cost structures and institutional purchasing behaviors, while exploring value-based propositions that link outcomes to therapy use.

Finally, implement advanced analytics for demand sensing and inventory optimization to reduce stockouts and improve service levels. By taking these coordinated actions, leaders can strengthen market responsiveness, improve clinical adoption, and build durable advantages in a landscape defined by regulatory nuance and shifting distribution dynamics

Robust multi-source methodology integrating practitioner interviews, regulatory review, and segmentation mapping to produce actionable commercial and clinical insights

This research synthesized primary and secondary evidence and applied a structured methodology to ensure the findings reflect contemporary clinical practice and commercial realities. Primary inputs included interviews with practicing veterinarians, procurement managers, and distribution executives to capture real-world perspectives on formulation preferences, channel performance, and clinical use cases. These qualitative insights were triangulated with secondary sources such as peer-reviewed pharmacology literature, regulatory documents, and industry technical reports to validate clinical and safety considerations.

Analytical methods incorporated segmentation mapping across form, species, end user, distribution channel, and dosage strength to reveal interdependencies that influence adoption and purchasing behavior. Supply chain and tariff impact analyses combined trade policy review with operational risk assessment techniques to identify likely strategic responses by manufacturers and distributors. Throughout the process, emphasis was placed on methodological transparency, with assumptions and data sources documented to enable reproducibility and to support follow-up inquiries by stakeholders.

In addition, the research applied scenario-based thinking to explore plausible operational adjustments under different regulatory and trade environments, ensuring recommendations are actionable across a range of real-world conditions. Together, these methods provide a rigorous foundation for the insights and recommendations presented in this report

Synthesis of clinical utility, distribution evolution, and supply chain imperatives highlighting strategic priorities for sustained commercial and patient outcome gains

In conclusion, maropitant citrate remains a cornerstone antiemetic in veterinary medicine, supported by clear clinical utility across perioperative care, chemotherapy adjunctive therapy, and management of gastrointestinal dysfunction. The landscape is being reshaped by greater emphasis on palatable oral formulations, diversified distribution channels including online pharmacies, and heightened supply chain scrutiny driven by trade policy shifts. These factors collectively demand that manufacturers, distributors, and veterinary providers adopt more integrated strategies that balance clinical needs with operational resiliency.

Furthermore, careful attention to segmentation-spanning form, species, end user, distribution channel, and dosage strength-enables stakeholders to tailor portfolios and go-to-market approaches that resonate with distinct practice types and regional market structures. Companies that align portfolio breadth with distribution flexibility and targeted clinician engagement will be better positioned to navigate regulatory complexity and evolving procurement behaviors.

Ultimately, the convergence of clinical innovation, digital distribution, and strategic supply chain planning presents significant opportunities for those who act decisively. Embracing these insights and implementing the strategic recommendations outlined will help organizations deliver better patient outcomes while strengthening commercial performance in a competitive and changing environment

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Maropitant Citrate Market, by Form

  • 8.1. Flavored Tablet
  • 8.2. Injectable Solution

9. Maropitant Citrate Market, by Species

  • 9.1. Cat
  • 9.2. Dog

10. Maropitant Citrate Market, by End User

  • 10.1. Animal Specialty Hospital
  • 10.2. Veterinary Clinic
  • 10.3. Veterinary Hospital

11. Maropitant Citrate Market, by Distribution Channel

  • 11.1. Offline Pharmacy
  • 11.2. Online Pharmacy
    • 11.2.1. Manufacturer Platform
    • 11.2.2. Third-Party Retailer

12. Maropitant Citrate Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Maropitant Citrate Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Maropitant Citrate Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Maropitant Citrate Market

16. China Maropitant Citrate Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alivira Animal Health Limited
  • 17.6. Ashish Life Science Pvt. Ltd.
  • 17.7. Aurobindo Pharma Limited
  • 17.8. Bimeda Holdings plc
  • 17.9. Boehringer Ingelheim International GmbH
  • 17.10. Ceva Sante Animale S.A.
  • 17.11. Dechra Pharmaceuticals PLC
  • 17.12. Elanco Animal Health Incorporated
  • 17.13. Hester Biosciences Limited
  • 17.14. HIPRA, S.A.
  • 17.15. Intas Pharmaceuticals Ltd.
  • 17.16. KVP Pharma + Veterinar Produkte GmbH
  • 17.17. Lasa Supergenerics Limited
  • 17.18. Merck Animal Health
  • 17.19. Neogen Corporation
  • 17.20. Norbrook Laboratories Limited
  • 17.21. Pharmgate Animal Health
  • 17.22. Sequent Scientific Limited
  • 17.23. Venkateshwara Hatcheries Limited
  • 17.24. Vetindia Pharmaceuticals Limited
  • 17.25. Vetoquinol S.A.
  • 17.26. Virbac S.A.
  • 17.27. Zim Laboratories Limited
  • 17.28. Zoetis Inc.
  • 17.29. Zydus Animal Health

LIST OF FIGURES

  • FIGURE 1. GLOBAL MAROPITANT CITRATE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MAROPITANT CITRATE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MAROPITANT CITRATE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MAROPITANT CITRATE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MAROPITANT CITRATE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MAROPITANT CITRATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY FLAVORED TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY FLAVORED TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY FLAVORED TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY CAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY CAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY CAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY DOG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY DOG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY DOG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY ANIMAL SPECIALTY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY ANIMAL SPECIALTY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY ANIMAL SPECIALTY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY VETERINARY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY VETERINARY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY VETERINARY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY VETERINARY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY VETERINARY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY VETERINARY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY OFFLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY OFFLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY OFFLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY MANUFACTURER PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY MANUFACTURER PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY MANUFACTURER PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY THIRD-PARTY RETAILER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY THIRD-PARTY RETAILER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY THIRD-PARTY RETAILER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS MAROPITANT CITRATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA MAROPITANT CITRATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 96. GCC MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GCC MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 98. GCC MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 99. GCC MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GCC MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. GCC MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 114. G7 MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. G7 MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 116. G7 MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 117. G7 MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. G7 MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. G7 MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 120. NATO MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. NATO MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 122. NATO MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 123. NATO MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NATO MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. NATO MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MAROPITANT CITRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES MAROPITANT CITRATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA MAROPITANT CITRATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. CHINA MAROPITANT CITRATE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 135. CHINA MAROPITANT CITRATE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA MAROPITANT CITRATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA MAROPITANT CITRATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA MAROPITANT CITRATE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)